Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period. [clinicaltrials_resource:f8d760031d5b96891af669ba7c46c17d]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period. [clinicaltrials_resource:f8d760031d5b96891af669ba7c46c17d]
Bio2RDF identifier
f8d760031d5b96891af669ba7c46c17d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f8d760031d5b96891af669ba7c46c17d
measure [clinicaltrials_vocabulary:measure]
Sustained Viral Response (SVR) ...... 2 or 24 week treatment period.
identifier
clinicaltrials_resource:f8d760031d5b96891af669ba7c46c17d
title
Sustained Viral Response (SVR) ...... 2 or 24 week treatment period.
@en
type
label
Sustained Viral Response (SVR) ...... 760031d5b96891af669ba7c46c17d]
@en